查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2111168

基因組醫學市場預測至2034年－全球分析（按產品和服務、技術、基因組醫學方法、檢測類型、檢體類型、臨床應用、最終用戶和地區分類）

Genomic Medicine Market Forecasts To 2034 - Global Analysis By Product & Service, Technology, Genomic Medicine Approach, Test Type, Sample Type, Clinical Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球基因組學市場規模將達到 497 億美元，並在預測期內以 17.5% 的複合年成長率成長，到 2034 年將達到 1807 億美元。

基因組醫學市場專注於利用遺傳和基因組資訊來改善疾病檢測、風險評估、治療選擇和患者管理的醫療保健解決方案。透過結合基因測序、分子診斷、基於 CRISPR 的基因編輯和計算數據分析等技術，基因組醫學能夠實現更個人化的臨床照護。這些方法有助於臨床醫生識別與疾病相關的基因突變，為個別患者制定個人化治療方案，並支持其做出明智的醫療決策。該市場涵蓋定序設備、診斷檢測、生物資訊平台、基因組分析服務和精準醫療應用，服務對象包括醫院、臨床檢查室、學術研究機構和生物製藥公司。

遺傳性疾病和罕見病患疾病率增加

遺傳性和罕見遺傳疾病負擔的日益加重，正推動基因組醫學在醫療保健領域的應用。由於傳統診斷技術往往無法識別這些疾病的潛在遺傳病因，基因組分析已成為至關重要的臨床工具。基因檢測使醫生能夠發現致病突變，做出精準診斷，並制定個人化的治療方案。醫學研究人員正利用基因組資訊來闡明疾病的生物機制，並尋找新的治療標靶。這些能力有助於改善患者管理，並鼓勵醫療保健專業人員和藥物研發人員擴大基因組技術在應對複雜遺傳疾病方面的應用。

基因組檢測和先進技術高成本

基因組醫學的成本仍然是一項重大挑戰。這主要是由於先進的定序設備、計算分析工具和檢查室基礎設施需要大量投資。醫療機構必須將資源用於培訓專家、品管和持續的系統維護，才能提供準確的基因組醫學服務。全面的基因檢測和結果解讀也會增加整體醫療成本，使許多患者和醫療服務提供者難以負擔。小規模醫院和實驗室在採用這些技術時往往面臨資金障礙，限制了它們將基因組醫學融入常規臨床實踐的能力，並減緩了其在不同醫療系統和地區的推廣。

群體基因組學與醫療保健的擴展

群體基因組學的廣泛應用為基因組醫學創造了新的機遇，它支持疾病預防和個人化健康管理。大規模基因研究使研究人員和醫療保健專業人員能夠識別遺傳疾病的風險因素，改善篩檢方案，並在症狀出現前指南預防干預。基於人群的基因組資訊也有助於更深入地了解不同人群的遺傳多樣性和疾病進展。各國政府、醫療機構和研究機構不斷擴大基因組學相關舉措，以加強公共衛生策略。這些進展正在提升基因組醫學在預防醫學和長期疾病管理的重要性。

對基因訊息的誤解

基因資訊分析中潛在的錯誤對基因組醫學構成重大威脅。由於某些基因變異的機制仍不甚明了，醫療專業人員難以完全確定其臨床意義。不準確的解讀會影響診斷、治療方案的選擇和患者諮詢，並降低基因組檢測結果的可靠性。檢查室操作規範、分析軟體和專家知識的差異進一步加劇了解讀的難度。持續更新基因組資料庫、進行專業培訓以及檢驗的分析方法對於減少錯誤、支持基因組醫學在臨床實踐中的可靠應用至關重要。

新冠疫情的影響：

新冠疫情顯著提升了整個醫療體系對基因組醫學的認知和應用，凸顯了基因測序和分子分析在理解感染疾病的重要性。醫療機構、研究機構和診斷檢查室加強了基因組相關能力，以追蹤病毒演化、提高診斷準確性並支持流行病學監測。生物技術公司、學術機構和公共衛生組織之間合作的加強加速了基因組技術融入常規醫療實踐的進程。這次疫情也加強了檢查室基礎設施建設，拓展了生物資訊能力，並凸顯了基因組醫學在疾病監測、個人化醫療和臨床研究中的長期作用。

在預測期內，「定序設備」細分市場預計將佔據最大的市場佔有率。

預計在預測期內，定序儀器領域將佔據最大的市場佔有率。這是因為定序平台是支撐整個醫療保健和生命科學領域基因組醫學的核心技術。這些平台能夠進行全面的基因分析，這對於診斷遺傳疾病、癌症譜分析、感染疾病研究以及製定個人化治療方案至關重要。醫療機構、研究機構和生物技術公司都依賴這些系統來產生可靠的基因組訊息，用於臨床和科學應用。隨著技術進步不斷提高定序效率、分析效能、擴充性和工作流程整合度，定序儀器在整個基因組醫學生態系統中的重要性日益凸顯。

預計在預測期內，「罕見遺傳疾病」細分市場將呈現最高的複合年成長率。

在預測期內，「罕見遺傳疾病」領域預計將呈現最高的成長率，因為基因組醫學為檢測傳統診斷方法難以確診的遺傳疾病提供了高度精準的工具。先進的定序和分子分析技術能夠幫助臨床醫生識別基因異常，指導制定個人化治療方案，並透過遺傳諮詢支持家族風險評估。醫院、專科診所和診斷實驗室正擴大將基因組檢測納入罕見疾病的常規評估流程。隨著基因組技術的不斷進步、研究合作的加強以及專業遺傳服務的普及，基因組醫學在有效管理罕見遺傳疾病方面的作用將持續擴大。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於該地區成熟的醫療保健生態系統，該系統廣泛應用基因組技術進行疾病診斷、精準醫療和生物醫學研究。醫療機構受益於先進的檢測基礎設施、經驗豐富的基因組學專家以及研究機構與生命科學公司之間緊密的合作。定序技術、分子診斷和生物資訊平台的普及，為基因組醫學的高效臨床應用提供了有力支持。憑藉對精準醫療的持續投入、基因組研究的創新以及強大的機構支持，北美正不斷鞏固其作為基因組醫學領先區域市場的地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療基礎設施的不斷完善、先進基因組技術的日益普及以及精準醫療在臨床實踐中的應用。該地區各國正透過投資定序實驗室、生物資訊平台和轉化醫學項目，不斷提升其基因組研究能力。醫療服務提供者擴大利用基因組檢測進行疾病診斷、制定個人化治療方案以及進行遺傳疾病篩檢。學術機構、生技公司、製藥公司和醫療系統之間的合作正在改善基因組服務的可近性，而持續的技術進步也推動了基因組醫學在各個臨床應用領域的更廣泛應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球基因組醫療保健市場：依產品與服務分類

  • 定序裝置
  • 試劑和耗材
  • 生物資訊軟體
  • 基因組檢測服務
  • 臨床口譯服務

第6章 全球基因體學市場：依技術分類

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 桑格定序
  • 微陣列
  • CRISPR基因編輯
  • 螢光原位雜合反應（FISH）
  • 數位PCR（dPCR）
  • 長讀長定定序

第7章：全球基因組醫學市場：依基因組醫學方法分類

  • 分子診斷
  • 精準醫療
  • 藥物基因體學
  • 基因治療
  • 基因編輯

第8章 全球基因體學市場：依檢測類型分類

  • 診斷測試
  • 預測性和無症狀檢測
  • 基因帶原檢測
  • 產前檢查
  • 新生兒篩檢
  • 藥物基因體學學檢測
  • 伴隨診斷檢查

第9章 全球基因體學市場：依樣本類型分類

  • 血
  • 組織
  • 唾液
  • 口腔黏膜拭子
  • 骨髓
  • 無細胞DNA（cfDNA）

第10章 全球基因體學市場：依臨床應用分類

  • 腫瘤學
  • 罕見遺傳疾病
  • 心血管疾病
  • 神經病變
  • 感染疾病
  • 生殖醫學
  • 產前和新生兒篩檢
  • 代謝性疾病
  • 免疫系統疾病

第11章 全球基因體學市場：依最終用戶分類

  • 醫院
  • 臨床實驗室
  • 診斷中心
  • 學術研究機構
  • 製藥和生物技術公司
  • 受託研究機構（CRO）

第12章 全球基因體學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第13章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第14章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第15章：公司簡介

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Pacific Biosciences of California, Inc.（PacBio）
  • Oxford Nanopore Technologies plc
  • BGI Genomics Co., Ltd.
  • Revvity, Inc.
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • Natera, Inc.
  • Myriad Genetics, Inc.
  • GeneDx Holdings Corp.
  • Tempus AI, Inc.
  • NeoGenomics, Inc.
  • Personalis, Inc.
  • GRAIL, Inc.
Product Code: SMRC38861

According to Stratistics MRC, the Global Genomic Medicine Market is accounted for $49.7 billion in 2026 and is expected to reach $180.7 billion by 2034 growing at a CAGR of 17.5% during the forecast period. The genomic medicine market focuses on healthcare solutions that utilize genetic and genomic information to enhance disease detection, risk assessment, treatment selection, and patient management. By combining technologies such as genome sequencing, molecular diagnostics, CRISPR-based gene editing, and computational data analysis, genomic medicine enables more personalized clinical care. These approaches help clinicians identify disease-related genetic mutations, tailor therapies to individual patients, and support informed medical decisions. The market includes sequencing instruments, diagnostic assays, bioinformatics platforms, genomic analysis services, and precision medicine applications serving hospitals, clinical laboratories, academic research organizations, and biopharmaceutical companies.

Market Dynamics:

Driver:

Increasing Prevalence of Genetic and Rare Diseases

A rising burden of inherited and uncommon genetic disorders is encouraging greater use of genomic medicine in healthcare. Traditional diagnostic techniques frequently fail to identify the underlying genetic causes of these diseases, making genomic analysis an important clinical tool. Genetic testing enables physicians to detect pathogenic variants, establish accurate diagnoses, and design individualized treatment strategies. Medical researchers use genomic information to understand disease biology and identify new therapeutic targets. These capabilities support improved patient management while encouraging healthcare providers and pharmaceutical developers to expand the use of genomic technologies in addressing complex genetic conditions.

Restraint:

High Cost of Genomic Testing and Advanced Technologies

The expense associated with genomic medicine remains a significant challenge because advanced sequencing equipment, computational analysis tools, and laboratory infrastructure require considerable investment. Healthcare organizations must allocate resources for specialized workforce training, quality control, and ongoing system maintenance to deliver accurate genomic services. Comprehensive genetic testing and interpretation also increase overall healthcare costs, reducing accessibility for many patients and providers. Smaller hospitals and laboratories often face financial barriers when adopting these technologies, limiting their ability to integrate genomic medicine into routine clinical practice and slowing its availability across different healthcare systems and regions.

Opportunity:

Expansion of Population Genomics and Preventive Healthcare

The broader implementation of population genomics is creating new opportunities for genomic medicine by supporting disease prevention and personalized health management. Large-scale genetic studies enable researchers and healthcare professionals to identify inherited disease risks, improve screening programs, and guide preventive interventions before symptoms appear. Population-based genomic information also enhances scientific understanding of genetic diversity and disease progression across different communities. Governments, healthcare institutions, and research organizations continue expanding genomic initiatives to strengthen public health strategies. These developments increase the importance of genomic medicine in preventive healthcare and long-term disease management.

Threat:

Misinterpretation of Genetic Information

The possibility of incorrectly analyzing genetic information represents an important threat to genomic medicine. Some genetic variants remain poorly understood, making it difficult for healthcare professionals to determine their clinical relevance with complete confidence. Inaccurate interpretation can affect diagnosis, treatment selection, and patient counseling while reducing confidence in genomic testing outcomes. Differences in laboratory practices, analytical software, and professional expertise further increase interpretation challenges. Continuous updates to genomic databases, specialized training, and validated analytical approaches are essential to reduce errors and support reliable implementation of genomic medicine in clinical practice.

Covid-19 Impact:

The COVID-19 pandemic significantly increased the visibility and application of genomic medicine across healthcare systems by demonstrating the importance of genomic sequencing and molecular analysis in understanding infectious diseases. Healthcare providers, research organizations, and diagnostic laboratories enhanced their genomic capabilities to track viral evolution, improve diagnostic accuracy, and support epidemiological monitoring. Greater collaboration among biotechnology companies, academic institutions, and public health agencies accelerated the integration of genomic technologies into routine healthcare practices. The experience also strengthened laboratory infrastructure, expanded bioinformatics capabilities, and emphasized the long-term role of genomic medicine in disease surveillance, personalized healthcare, and clinical research.

The Sequencing Instruments segment is expected to be the largest during the forecast period

The Sequencing Instruments segment is expected to account for the largest market share during the forecast period because sequencing platforms serve as the core technology supporting genomic medicine across healthcare and life sciences. They enable comprehensive genetic analysis required for diagnosing inherited disorders, cancer profiling, infectious disease research, and personalized treatment planning. Healthcare providers, research organizations, and biotechnology companies depend on these systems to produce reliable genomic information for clinical and scientific applications. Ongoing technological enhancements that improve sequencing efficiency, analytical performance, scalability, and workflow integration continue to reinforce the importance of sequencing instruments throughout the genomic medicine ecosystem.

The Rare Genetic Disorders segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Rare Genetic Disorders segment is predicted to witness the highest growth rate because genomic medicine provides highly accurate tools for detecting inherited diseases that often remain undiagnosed through traditional diagnostic approaches. Advanced sequencing and molecular analysis help clinicians identify genetic abnormalities, guide individualized treatment decisions, and support family risk assessment through genetic counseling. Hospitals, specialty clinics, and diagnostic laboratories are increasingly incorporating genomic testing into routine evaluation of rare diseases. Ongoing improvements in genomic technologies, stronger research collaborations, and broader availability of specialized genetic services continue to expand the role of genomic medicine in managing rare genetic disorders effectively.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, because the region possesses a mature healthcare ecosystem that widely utilizes genomic technologies for disease diagnosis, precision treatment, and biomedical research. Healthcare organizations benefit from sophisticated laboratory infrastructure, experienced genomic specialists, and strong collaboration between research institutes and life sciences companies. The widespread use of sequencing technologies, molecular diagnostics, and bioinformatics platforms supports efficient clinical implementation of genomic medicine. Ongoing commitment to precision healthcare, innovation in genomic research, and strong institutional support continues to position North America as the leading regional market for genomic medicine.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to expanding healthcare infrastructure, increasing adoption of advanced genomic technologies, and growing integration of precision medicine into clinical practice. Countries across the region are strengthening genomic research capabilities through investments in sequencing laboratories, bioinformatics platforms, and translational medicine initiatives. Healthcare providers are increasingly utilizing genomic testing for disease diagnosis, personalized treatment planning, and hereditary disease screening. Collaboration among academic institutions, biotechnology companies, pharmaceutical organizations, and healthcare systems is enhancing access to genomic services, while continuous technological advancements support broader implementation of genomic medicine across diverse clinical applications.

Key players in the market

Some of the key players in Genomic Medicine Market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Agilent Technologies, Inc., Pacific Biosciences of California, Inc. (PacBio), Oxford Nanopore Technologies plc, BGI Genomics Co., Ltd., Revvity, Inc., Exact Sciences Corporation, Guardant Health, Inc., Natera, Inc., Myriad Genetics, Inc., GeneDx Holdings Corp., Tempus AI, Inc., NeoGenomics, Inc., Personalis, Inc. and GRAIL, Inc.

Key Developments:

In May 2026, Oxford Nanopore Technologies announced a strategic collaboration with Werfen to support the development of advanced transplant assays.

In May 2026, Illumina strengthened collaborations with governments, health systems, and research institutions to expand population-scale genomics, sovereign data stewardship, and national precision health initiatives.

In January 2026, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to leverage artificial intelligence for advancing scientific instrumentation and improving laboratory performance.

Product & Services Covered:

  • Sequencing Instruments
  • Reagents & Consumables
  • Bioinformatics Software
  • Genomic Testing Services
  • Clinical Interpretation Services

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Sanger Sequencing
  • Microarray
  • CRISPR Genome Editing
  • Fluorescence In Situ Hybridization (FISH)
  • Digital PCR (dPCR)
  • Long-Read Sequencing

Genomic Medicine Approach Covered:

  • Molecular Diagnostics
  • Precision Medicine
  • Pharmacogenomics
  • Gene Therapy
  • Gene Editing

Test Types Covered:

  • Diagnostic Testing
  • Predictive & Presymptomatic Testing
  • Carrier Testing
  • Prenatal Testing
  • Newborn Screening
  • Pharmacogenomic Testing
  • Companion Diagnostic Testing

Sample Types Covered:

  • Blood
  • Tissue
  • Saliva
  • Buccal Swab
  • Bone Marrow
  • Cell-Free DNA (cfDNA)

Clinical Applications Covered:

  • Oncology
  • Rare Genetic Disorders
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Reproductive Health
  • Prenatal & Newborn Screening
  • Metabolic Disorders
  • Immunological Disorders

End Users Covered:

  • Hospitals
  • Clinical Laboratories
  • Diagnostic Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Genomic Medicine Market, By Product & Service

  • 5.1 Sequencing Instruments
  • 5.2 Reagents & Consumables
  • 5.3 Bioinformatics Software
  • 5.4 Genomic Testing Services
  • 5.5 Clinical Interpretation Services

6 Global Genomic Medicine Market, By Technology

  • 6.1 Next-Generation Sequencing (NGS)
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Sanger Sequencing
  • 6.4 Microarray
  • 6.5 CRISPR Genome Editing
  • 6.6 Fluorescence In Situ Hybridization (FISH)
  • 6.7 Digital PCR (dPCR)
  • 6.8 Long-Read Sequencing

7 Global Genomic Medicine Market, By Genomic Medicine Approach

  • 7.1 Molecular Diagnostics
  • 7.2 Precision Medicine
  • 7.3 Pharmacogenomics
  • 7.4 Gene Therapy
  • 7.5 Gene Editing

8 Global Genomic Medicine Market, By Test Type

  • 8.1 Diagnostic Testing
  • 8.2 Predictive & Presymptomatic Testing
  • 8.3 Carrier Testing
  • 8.4 Prenatal Testing
  • 8.5 Newborn Screening
  • 8.6 Pharmacogenomic Testing
  • 8.7 Companion Diagnostic Testing

9 Global Genomic Medicine Market, By Sample Type

  • 9.1 Blood
  • 9.2 Tissue
  • 9.3 Saliva
  • 9.4 Buccal Swab
  • 9.5 Bone Marrow
  • 9.6 Cell-Free DNA (cfDNA)

10 Global Genomic Medicine Market, By Clinical Application

  • 10.1 Oncology
  • 10.2 Rare Genetic Disorders
  • 10.3 Cardiovascular Diseases
  • 10.4 Neurological Disorders
  • 10.5 Infectious Diseases
  • 10.6 Reproductive Health
  • 10.7 Prenatal & Newborn Screening
  • 10.8 Metabolic Disorders
  • 10.9 Immunological Disorders

11 Global Genomic Medicine Market, By End User

  • 11.1 Hospitals
  • 11.2 Clinical Laboratories
  • 11.3 Diagnostic Centers
  • 11.4 Academic & Research Institutes
  • 11.5 Pharmaceutical & Biotechnology Companies
  • 11.6 Contract Research Organizations (CROs)

12 Global Genomic Medicine Market, By Geography

  • 12.1 North America
    • 12.1.1 United States
    • 12.1.2 Canada
    • 12.1.3 Mexico
  • 12.2 Europe
    • 12.2.1 United Kingdom
    • 12.2.2 Germany
    • 12.2.3 France
    • 12.2.4 Italy
    • 12.2.5 Spain
    • 12.2.6 Netherlands
    • 12.2.7 Belgium
    • 12.2.8 Sweden
    • 12.2.9 Switzerland
    • 12.2.10 Poland
    • 12.2.11 Rest of Europe
  • 12.3 Asia Pacific
    • 12.3.1 China
    • 12.3.2 Japan
    • 12.3.3 India
    • 12.3.4 South Korea
    • 12.3.5 Australia
    • 12.3.6 Indonesia
    • 12.3.7 Thailand
    • 12.3.8 Malaysia
    • 12.3.9 Singapore
    • 12.3.10 Vietnam
    • 12.3.11 Rest of Asia Pacific
  • 12.4 South America
    • 12.4.1 Brazil
    • 12.4.2 Argentina
    • 12.4.3 Colombia
    • 12.4.4 Chile
    • 12.4.5 Peru
    • 12.4.6 Rest of South America
  • 12.5 Rest of the World (RoW)
    • 12.5.1 Middle East
      • 12.5.1.1 Saudi Arabia
      • 12.5.1.2 United Arab Emirates
      • 12.5.1.3 Qatar
      • 12.5.1.4 Israel
      • 12.5.1.5 Rest of Middle East
    • 12.5.2 Africa
      • 12.5.2.1 South Africa
      • 12.5.2.2 Egypt
      • 12.5.2.3 Morocco
      • 12.5.2.4 Rest of Africa

13 Strategic Market Intelligence

  • 13.1 Industry Value Network and Supply Chain Assessment
  • 13.2 White-Space and Opportunity Mapping
  • 13.3 Product Evolution and Market Life Cycle Analysis
  • 13.4 Channel, Distributor, and Go-to-Market Assessment

14 Industry Developments and Strategic Initiatives

  • 14.1 Mergers and Acquisitions
  • 14.2 Partnerships, Alliances, and Joint Ventures
  • 14.3 New Product Launches and Certifications
  • 14.4 Capacity Expansion and Investments
  • 14.5 Other Strategic Initiatives

15 Company Profiles

  • 15.1 Illumina, Inc.
  • 15.2 Thermo Fisher Scientific Inc.
  • 15.3 F. Hoffmann-La Roche Ltd.
  • 15.4 QIAGEN N.V.
  • 15.5 Agilent Technologies, Inc.
  • 15.6 Pacific Biosciences of California, Inc. (PacBio)
  • 15.7 Oxford Nanopore Technologies plc
  • 15.8 BGI Genomics Co., Ltd.
  • 15.9 Revvity, Inc.
  • 15.10 Exact Sciences Corporation
  • 15.11 Guardant Health, Inc.
  • 15.12 Natera, Inc.
  • 15.13 Myriad Genetics, Inc.
  • 15.14 GeneDx Holdings Corp.
  • 15.15 Tempus AI, Inc.
  • 15.16 NeoGenomics, Inc.
  • 15.17 Personalis, Inc.
  • 15.18 GRAIL, Inc.

List of Tables

  • Table 1 Global Genomic Medicine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Genomic Medicine Market Outlook, By Product & Service (2023-2034) ($MN)
  • Table 3 Global Genomic Medicine Market Outlook, By Sequencing Instruments (2023-2034) ($MN)
  • Table 4 Global Genomic Medicine Market Outlook, By Reagents & Consumables (2023-2034) ($MN)
  • Table 5 Global Genomic Medicine Market Outlook, By Bioinformatics Software (2023-2034) ($MN)
  • Table 6 Global Genomic Medicine Market Outlook, By Genomic Testing Services (2023-2034) ($MN)
  • Table 7 Global Genomic Medicine Market Outlook, By Clinical Interpretation Services (2023-2034) ($MN)
  • Table 8 Global Genomic Medicine Market Outlook, By Technology (2023-2034) ($MN)
  • Table 9 Global Genomic Medicine Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 10 Global Genomic Medicine Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 11 Global Genomic Medicine Market Outlook, By Sanger Sequencing (2023-2034) ($MN)
  • Table 12 Global Genomic Medicine Market Outlook, By Microarray (2023-2034) ($MN)
  • Table 13 Global Genomic Medicine Market Outlook, By CRISPR Genome Editing (2023-2034) ($MN)
  • Table 14 Global Genomic Medicine Market Outlook, By Fluorescence In Situ Hybridization (FISH) (2023-2034) ($MN)
  • Table 15 Global Genomic Medicine Market Outlook, By Digital PCR (dPCR) (2023-2034) ($MN)
  • Table 16 Global Genomic Medicine Market Outlook, By Long-Read Sequencing (2023-2034) ($MN)
  • Table 17 Global Genomic Medicine Market Outlook, By Genomic Medicine Approach (2023-2034) ($MN)
  • Table 18 Global Genomic Medicine Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 19 Global Genomic Medicine Market Outlook, By Precision Medicine (2023-2034) ($MN)
  • Table 20 Global Genomic Medicine Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
  • Table 21 Global Genomic Medicine Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 22 Global Genomic Medicine Market Outlook, By Gene Editing (2023-2034) ($MN)
  • Table 23 Global Genomic Medicine Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 24 Global Genomic Medicine Market Outlook, By Diagnostic Testing (2023-2034) ($MN)
  • Table 25 Global Genomic Medicine Market Outlook, By Predictive & Presymptomatic Testing (2023-2034) ($MN)
  • Table 26 Global Genomic Medicine Market Outlook, By Carrier Testing (2023-2034) ($MN)
  • Table 27 Global Genomic Medicine Market Outlook, By Prenatal Testing (2023-2034) ($MN)
  • Table 28 Global Genomic Medicine Market Outlook, By Newborn Screening (2023-2034) ($MN)
  • Table 29 Global Genomic Medicine Market Outlook, By Pharmacogenomic Testing (2023-2034) ($MN)
  • Table 30 Global Genomic Medicine Market Outlook, By Companion Diagnostic Testing (2023-2034) ($MN)
  • Table 31 Global Genomic Medicine Market Outlook, By Sample Type (2023-2034) ($MN)
  • Table 32 Global Genomic Medicine Market Outlook, By Blood (2023-2034) ($MN)
  • Table 33 Global Genomic Medicine Market Outlook, By Tissue (2023-2034) ($MN)
  • Table 34 Global Genomic Medicine Market Outlook, By Saliva (2023-2034) ($MN)
  • Table 35 Global Genomic Medicine Market Outlook, By Buccal Swab (2023-2034) ($MN)
  • Table 36 Global Genomic Medicine Market Outlook, By Bone Marrow (2023-2034) ($MN)
  • Table 37 Global Genomic Medicine Market Outlook, By Cell-Free DNA (cfDNA) (2023-2034) ($MN)
  • Table 38 Global Genomic Medicine Market Outlook, By Clinical Application (2023-2034) ($MN)
  • Table 39 Global Genomic Medicine Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 40 Global Genomic Medicine Market Outlook, By Rare Genetic Disorders (2023-2034) ($MN)
  • Table 41 Global Genomic Medicine Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 42 Global Genomic Medicine Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 43 Global Genomic Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 44 Global Genomic Medicine Market Outlook, By Reproductive Health (2023-2034) ($MN)
  • Table 45 Global Genomic Medicine Market Outlook, By Prenatal & Newborn Screening (2023-2034) ($MN)
  • Table 46 Global Genomic Medicine Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 47 Global Genomic Medicine Market Outlook, By Immunological Disorders (2023-2034) ($MN)
  • Table 48 Global Genomic Medicine Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 Global Genomic Medicine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 50 Global Genomic Medicine Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 51 Global Genomic Medicine Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 52 Global Genomic Medicine Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 53 Global Genomic Medicine Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 54 Global Genomic Medicine Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.